Compare TRX & STIM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TRX | STIM |
|---|---|---|
| Founded | 1990 | 2003 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Medical/Dental Instruments |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 253.9M | 120.4M |
| IPO Year | 2002 | 2018 |
| Metric | TRX | STIM |
|---|---|---|
| Price | $1.15 | $2.77 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 1 |
| Target Price | $1.70 | ★ $3.00 |
| AVG Volume (30 Days) | ★ 3.2M | 2.7M |
| Earning Date | 04-15-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 57.25 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $52,776,000.00 |
| Revenue This Year | $84.84 | $11.10 |
| Revenue Next Year | $96.90 | $11.92 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.39 | $0.80 |
| 52 Week High | $2.80 | $3.71 |
| Indicator | TRX | STIM |
|---|---|---|
| Relative Strength Index (RSI) | 57.78 | 57.72 |
| Support Level | $0.82 | $1.21 |
| Resistance Level | $1.34 | N/A |
| Average True Range (ATR) | 0.06 | 0.19 |
| MACD | -0.01 | -0.07 |
| Stochastic Oscillator | 45.45 | 19.23 |
TRX Gold Corp is a high-margin and growing gold company advancing the Buckreef Gold Project in Tanzania. Buckreef Gold includes an established open-pit operation and approximately 2,000 tonnes per day process plant with upside potential demonstrated. The group is focused on creating both near-term and long-term shareholder value by increasing gold production to generate positive cash flow to fund the expansion as outlined in the PEA and grow Mineral Resources through exploration. TRX Gold's actions are led by the highest environmental, social, and corporate governance (ESG) standards, evidenced by the relationships and programs that the Company has developed during its nearly two decades of presence in the Geita Region, Tanzania.
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.